Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders

References

• Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin Transl Immunol. 2016;5:e85.
   PubMed Web of Science ®Google Scholar
• Al-Ofi EA, Al-Ghamdi BS. High-mobility group box 1, an endogenous ligand of toll-like receptors 2 and 4, induces astroglial inflammation via nuclear factor kappa B pathway. Folia Morphol. 2019;78:10–16.
   Web of Science ®Google Scholar
• Wardill HR, Van Sebille YZA, Mander KA, et al. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treat Rev. 2015;41:122–128.
   PubMed Web of Science ®Google Scholar
• Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediators Inflamm. 2016;2016:1–9.
   Google Scholar
• Rahimifard M, Maqbool F, Moeini-Nodeh S, et al. Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 2017;36:11–19.
   PubMed Web of Science ®Google Scholar
• Oblak A, Jerala R. The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex. Mol Immunol. 2015;63:134–142.
   PubMed Web of Science ®Google Scholar
• Bahrun U, Kimoto M, Tsukamoto H, et al. Preparation and characterization of agonistic monoclonal antibodies against toll-like receptor 4-MD-2 complex. Hybridoma. 2007;26:393–400.
   PubMedGoogle Scholar
• Ohta S, Bahrun U, Shimazu R, et al. Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the toll-like receptor 4/MD-2 complex. Clin Vaccine Immunol. 2006;13:1131–1136.
   PubMedGoogle Scholar
• Rajaiah R, Perkins DJ, Ireland DDC, et al. CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance. Proc Natl Acad Sci. 2015;112:8391–8396.
   PubMed Web of Science ®Google Scholar
• Fu R, Shen Q, Xu P, et al. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49:1422–1434.
   PubMed Web of Science ®Google Scholar
• Esen N, Kielian T. Central role for MyD88 in the responses of microglia to pathogen-associated molecular patterns. J Immunol. 2014;176:6802–6811.
   Google Scholar
• Zanoni I, Ostuni R, Marek LR, et al. CD14 controls the LPS-induced endocytosis of toll-like receptor 4. Cell. 2011;147:868–880.
   PubMed Web of Science ®Google Scholar
• Wang J, Kobayashi M, Han M, et al. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol. 2002;118:638–645.
   PubMed Web of Science ®Google Scholar
• Ruckdeschel K, Pfaffinger G, Haase R, et al. Signaling of apoptosis through TLRs critically involves toll/IL-1 receptor domain-containing adapter inducing IFN-β, but not MyD88, in bacteria-infected murine macrophages. J Immunol. 2004;173:3320–3328.
   PubMed Web of Science ®Google Scholar
• Qin H, Niyongere SA, Lee SJ, et al. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol. 2008;181:3167–3176.
   PubMed Web of Science ®Google Scholar
• Płóciennikowska A, Hromada-Judycka A, Borzęcka K, et al. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72:557–581.
   PubMed Web of Science ®Google Scholar
• Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014;5:1–15.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.
   PubMed Web of Science ®Google Scholar
• Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;34:433–454.
   PubMed Web of Science ®Google Scholar
• Schroder K, Irvine KM, Taylor MS, et al. Conservation and divergence in toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci. 2012;109:E944–E953.
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Ravid R, Gveric D, et al. Broad expression of toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol. 2002;61:1013–1021.
   PubMed Web of Science ®Google Scholar
• Sankowski R, Mader S, Valdes-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.
   PubMed Web of Science ®Google Scholar
• Gambuzza M, Licata N, Palella E, et al. Targeting toll-like receptors: emerging therapeutics for multiple sclerosis management. J Neuroimmunol. 2011;239:1–12.
   PubMed Web of Science ®Google Scholar
• Buchanan MM, Hutchinson M, Watkins LR, et al. Toll-like receptor 4 in CNS pathologies. J Neurochem. 2010;114:13–27.
   PubMed Web of Science ®Google Scholar
• Chavarría C, Rodríguez-Bottero S, Quijano C, et al. Impact of monomeric, oligomeric and fibrillar alpha-synuclein on astrocyte reactivity and toxicity to neurons. Biochem J. 2018;475:3153–3169.
   PubMed Web of Science ®Google Scholar
• Rannikko EH, Weber SS, Kahle PJ. Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci. 2015;16:57.
   PubMed Web of Science ®Google Scholar
• Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem. 2007;20:947–956.
   PubMed Web of Science ®Google Scholar
• Land WG. The role of damage-associated molecular patterns in human diseases: part I - promoting inflammation and immunity. Sultan Qaboos Univ Med J. 2015;15:e9–e21.
   PubMedGoogle Scholar
• Tahara K, Kim HD, Jin JJ, et al. Role of toll-like receptor signalling in Aβ uptake and clearance. Brain. 2006;129:3006–3019.
   PubMed Web of Science ®Google Scholar
• Qin Y, Liu Y, Hao W, et al. Stimulation of TLR4 attenuates Alzheimer’s disease–related symptoms and pathology in tau-transgenic mice. J Immunol. 2016;197:3281–3292.
   PubMed Web of Science ®Google Scholar
• Shen Y, Qin H, Chen J, et al. Postnatal activation of TLR4 in astrocytes promotes excitatory synaptogenesis in hippocampal neurons. J Cell Biol. 2016;215:719–734.
   PubMed Web of Science ®Google Scholar
• Gorina R, Font-Nieves M, Márquez-Kisinousky L, et al. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFκB signaling, MAPK, and Jak1/Stat1 pathways. Glia. 2011;59:242–255.
   PubMed Web of Science ®Google Scholar
• Henneberger C, Steinhäuser C. Astrocytic TLR4 at the crossroads of inflammation and seizure susceptibility. J Cell Biol. 2016;215:607–609.
   PubMed Web of Science ®Google Scholar
• Delgado M, Singh S, De Haro S, et al. Autophagy and pattern recognition receptors in innate immunity. Immunol Rev. 2009;227:189–202.
   PubMed Web of Science ®Google Scholar
• Aurelian L, Warnock KT, Balan I, et al. TLR4 signaling in VTA dopaminergic neurons regulates impulsivity through tyrosine hydroxylase modulation. Transl Psychiatry. 2016;6:e815.
   PubMed Web of Science ®Google Scholar
• Grasselli C, Ferrari D, Zalfa C, et al. Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiation. Cell Death Dis. 2018;9:280.
   PubMed Web of Science ®Google Scholar
• Yang Y, Han C, Guo L, et al. High expression of the HMGB1–TLR4 axis and its downstream signaling factors in patients with Parkinson’s disease and the relationship of pathological staging. Brain Behav. 2018;8:e00948.
   PubMed Web of Science ®Google Scholar
• Owens T. Toll-like receptors in neurodegeneration. Curr Top Microbiol Immunol. 2009;336:105–120.
   PubMed Web of Science ®Google Scholar
• Neher JJ, Neniskyte U, Zhao J-W, et al. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol. 2011;186:4973–4983.
   PubMed Web of Science ®Google Scholar
• Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2–22.
   PubMed Web of Science ®Google Scholar
• Yao L, Kan EM, Lu J, et al. Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J Neuroinflammation. 2013;10:785.
   Web of Science ®Google Scholar
• Madeira JM, Little JP, Klegeris A. Microglia secretome: from neurotoxins to neurotrophins. In: Kaur C, Ling EA, editors. Microglia: biology, Functions and Roles in Disease. New York: Nova Publishers; 2012. p. 73–92.
   Google Scholar
• Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217:459–472.
   PubMed Web of Science ®Google Scholar
• Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab. 2004;24:133–150.
   PubMed Web of Science ®Google Scholar
• Martínez-Valverde T, Sánchez-Guerrero A, Vidal-Jorge M, et al. Characterization of the ionic profile of the extracellular space of the injured and ischemic brain: a microdialysis study. J Neurotrauma. 2016;34:74–85.
   PubMed Web of Science ®Google Scholar
• Paudel YN, Shaikh MF, Chakraborti A, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci. 2018;12:628.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang Y, Liang X, et al. Toll-like receptor 4 knockdown attenuates brain damage and neuroinflammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation. Cell Mol Neurobiol. 2018;38:1009–1019.
   PubMed Web of Science ®Google Scholar
• Yang QW, Li JC, Lu FL, et al. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab. 2008;28:1588–1596.
   PubMed Web of Science ®Google Scholar
• Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53:1181–1194.
   PubMed Web of Science ®Google Scholar
• Calvo-Rodríguez M, de la Fuente C, García-Durillo M, et al. Aging and amyloid β oligomers enhance TLR4 expression, LPS-induced Ca2+ responses, and neuron cell death in cultured rat hippocampal neurons. J Neuroinflammation. 2017;14:24.
   PubMed Web of Science ®Google Scholar
• Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349–360.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11.
   PubMed Web of Science ®Google Scholar
• Marta M, Andersson Å, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol. 2008;38:565–575.
   PubMed Web of Science ®Google Scholar
• Van Langelaar J, Van Der Vuurst De Vries RM, Janssen M, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. 2018;141:1334–1349.
   PubMed Web of Science ®Google Scholar
• Bogie JFJ, Stinissen P, Hendriks JJA. Macrophage subsets and microglia in multiple sclerosis. Acta Neuropathol. 2014;128:191–213.
   PubMed Web of Science ®Google Scholar
• Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev. 2009;8:506–509.
   PubMed Web of Science ®Google Scholar
• Träger U, Andre R, Lahiri N, et al. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation. Brain. 2014;137:819–833.
   PubMed Web of Science ®Google Scholar
• Estrada Sánchez AM, Mejía-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res. 2008;39:265–276.
   PubMed Web of Science ®Google Scholar
• Griffioen K, Mattson MP, Okun E. Deficiency of toll-like receptors 2, 3 or 4 extends life expectancy in Huntington’s disease mice. Heliyon. 2018;4:e00508.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV. Astrogliosis. Cold Spring Harb Perspect Biol. 2015;7:a020420.
   Web of Science ®Google Scholar
• Patel AJ, Gray CW. Neurotrophic factors produced by astrocytes involved in the regulation of cholinergic neurons in the central nervous system. Biol Pathol Astrocyte-Neuron Interact. 2013;2:103–115.
   Google Scholar
• Morizawa YM, Hirayama Y, Ohno N, et al. Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nat Commun. 2017;8:28.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang L, Kallakuri S, et al. Quantitative relationship between axonal injury and mechanical response in a rodent head impact acceleration model. J Neurotrauma. 2011;28:1767–1782.
   PubMed Web of Science ®Google Scholar
• Holley JE, Gveric D, Newcombe J, et al. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol. 2003;29:434–444.
   PubMed Web of Science ®Google Scholar
• Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379–387.
   PubMed Web of Science ®Google Scholar
• Zou J, Crews FT. Glutamate/NMDA excitotoxicity and HMGB1/TLR4 neuroimmune toxicity converge as components of neurodegeneration. AIMS Mol Sci. 2015;2:77–100.
   Web of Science ®Google Scholar
• Cui J, Yu S, Li Y, et al. Direct binding of toll-like receptor 4 to ionotropic glutamate receptor N-methyl-D-aspartate subunit 1 induced by lipopolysaccharide in microglial cells N9 and EOC 20. Int J Mol Med. 2018;41:1323–1330.
   PubMed Web of Science ®Google Scholar
• Butchbach MER, Tian G, Guo H, et al. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem. 2004;279:34388–34396.
   PubMed Web of Science ®Google Scholar
• Lubetzki C, Stankoff B. Demyelination in multiple sclerosis. Handb Clin Neurol. 2014;122:89–99.
   PubMedGoogle Scholar
• Podbielska M, Banik NL, Kurowska E, et al. Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 2013;3:1282–1324.
   PubMedGoogle Scholar
• Dulamea AO. Role of oligodendrocyte dysfunction in demyelination, remyelination and neurodegeneration in multiple sclerosis. Adv Exp Med Biol. 2017;958:91–127.
   PubMed Web of Science ®Google Scholar
• Skripuletz T, Miller E, Grote L, et al. Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. Brain Behav Immun. 2011;25:1592–1606.
   PubMed Web of Science ®Google Scholar
• Church JS, Kigerl KA, Lerch JK, et al. TLR4 deficiency impairs oligodendrocyte gformation in the injured spinal cord. J Neurosci. 2016;36:6352–6364.
   PubMed Web of Science ®Google Scholar
• Church JS, Milich LM, Lerch JK, et al. E6020, a synthetic TLR4 agonist, accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord. Glia. 2017;65:883–899.
   PubMed Web of Science ®Google Scholar
• Cai Z, Xiao M. Oligodendrocytes and Alzheimer’s disease. Int J Neurosci. 2016;126:97–104.
   PubMed Web of Science ®Google Scholar
• Botelho RJ, Grinstein S. Phagocytosis. Curr Biol. 2011;21:R533–R538.
   PubMed Web of Science ®Google Scholar
• Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2013;20:460–473.
   PubMed Web of Science ®Google Scholar
• Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer’s disease. Glia. 2018;66:637–653.
   PubMed Web of Science ®Google Scholar
• Rajbhandari L, Tegenge MA, Shrestha S, et al. Toll-like receptor 4 deficiency impairs microglial phagocytosis of degenerating axons. Glia. 2014;62:1982–1991.
   PubMed Web of Science ®Google Scholar
• He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67–93.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. TLR4 signaling: negative regulation by degradation. Blood. 2007;110:794.
   Web of Science ®Google Scholar
• Tang S-C, Lathia JD, Selvaraj PK, et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol. 2008;213:114–121.
   PubMed Web of Science ®Google Scholar
• Jung DY, Lee H, Jung B-Y, et al. TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-β as a decision maker. J Immunol. 2005;174:6467–6476.
   PubMed Web of Science ®Google Scholar
• Veenith TV, Carter EL, Geeraerts T, et al. Pathophysiologic mechanisms of cerebral ischemia and diffusion hypoxia in traumatic brain injury. JAMA Neurol. 2016;73:542–550.
   PubMed Web of Science ®Google Scholar
• Washington PM, Morffy N, Parsadanian M, et al. Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-beta in an Alzheimer’s disease mouse model. J Neurotrauma. 2013;31:125–134.
   PubMed Web of Science ®Google Scholar
• Petrou M, Dwamena BA, Foerster BR, et al. Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord. 2015;30:928–935.
   PubMed Web of Science ®Google Scholar
• Kalaitzakis ME, Graeber MB, Gentleman SM, et al. Striatal β-amyloid deposition in Parkinson’s disease with dementia. J Neuropathol Exp Neurol. 2008;67:155–161.
   PubMedGoogle Scholar
• Bhadbhade A, Cheng DW. Amyloid precursor protein processing in Alzheimer’s disease. Iran J Child Neurol. 2012;6:1–4.
   Google Scholar
• Zheng Q, Huang T, Zhang L, et al. Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases. Front Aging Neurosci. 2016;8:303.
   PubMed Web of Science ®Google Scholar
• Stefanova N, Fellner L, Reindl M, et al. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179:954–963.
   PubMed Web of Science ®Google Scholar
• Mullin S, Schapira AHV. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin. 2015;33:1–17.
   PubMed Web of Science ®Google Scholar
• Bourdenx M, Bezard E, Dehay B. Lysosomes and alpha-synuclein form a dangerous duet leading to neuronal cell death. Front Neuroanat. 2014;8:83.
   PubMed Web of Science ®Google Scholar
• Woerman AL, Kazmi SA, Patel S, et al. MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathol. 2018;135:49–63.
   PubMed Web of Science ®Google Scholar
• Beyer K, Domingo-Sàbat M, Ariza A. Molecular pathology of Lewy body diseases. Int J Mol Sci. 2009;10:724–745.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Tanji K, Mori F, et al. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology. 2007;27:494–506.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656–664.
   PubMed Web of Science ®Google Scholar
• Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem. 2008;15:2321–2328.
   PubMed Web of Science ®Google Scholar
• Yan X, Uronen RL, Huttunen HJ. The interaction of α-synuclein and tau: a molecular conspiracy in neurodegeneration? Semin Cell Dev Biol. 2018;5:S1084–9521.
   Google Scholar
• Tidswell M, Tillis W, Larosa SP, et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010;38:72–83.
   PubMed Web of Science ®Google Scholar
• Lucas K, Maes M. Role of the toll-like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48:190–204.
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Muroi M, Tanamoto K. A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-κB and in vivo toxicity. Eur J Pharmacol. 2008;594:152–156.
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sha T, Ii M, et al. Selective inhibition of toll-like receptor 4 signaling by the small molecule TAK-242. Crit Care. 2006;10:P154–P154.
   PubMedGoogle Scholar
• Shah N, Montes De Oca M, Jover-Cobos M, et al. Role of toll-like receptor 4 in mediating multiorgan dysfunction in mice with acetaminophen induced acute liver failure. Liver Transplant. 2013;19:751–761.
   PubMed Web of Science ®Google Scholar
• Fellner A, Barhum Y, Angel A, et al. Toll-Like receptor-4 inhibitor TAK-242 attenuates motor dysfunction and spinal cord pathology in an amyotrophic lateral sclerosis mouse model. Int J Mol Sci. 2017;18:1666.
   Web of Science ®Google Scholar
• Palmer C, Peri F, Neumann F, et al. The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling. Innate Immun. 2018;24:411–421.
   PubMed Web of Science ®Google Scholar
• Perrin-Cocon L, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep. 2017;7:40791.
   PubMed Web of Science ®Google Scholar
• Fort MM, Mozaffarian A, Stöver AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005;174:6416–6423.
   PubMed Web of Science ®Google Scholar
• Oda M, Yamamoto H, Shibutani M, et al. Vizantin inhibits endotoxin-mediated immune responses via the TLR 4/MD-2 complex. J Immunol. 2014;193:4507–4514.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Oda M, Kanno M, et al. Chemical hybridization of vizantin and lipid A to generate a novel LPS antagonist. Chem Pharm Bull Pharm Bull. 2015;64:246–257.
   PubMed Web of Science ®Google Scholar
• Oda M, Kurosawa M, Yamamoto H, et al. Sulfated vizantin induces formation of macrophage extracellular traps. Microbiol Immunol. 2018;62:310–316.
   PubMed Web of Science ®Google Scholar
• Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist eritoran protects mice from lethal influenza infection. Nature. 2013;497:498–502.
   PubMed Web of Science ®Google Scholar
• Lin M, Yiu WH, Li RX, et al. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int. 2013;83:887–900.
   PubMed Web of Science ®Google Scholar
• Cighetti R, Ciaramelli C, Sestito SE, et al. Modulation of CD14 and TLR4×MD-2 activities by a synthetic lipid A mimetic. ChemBioChem. 2014;15:250–258.
   PubMed Web of Science ®Google Scholar
• Cluff CW, Baldridge JR, Stöver AG, et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun. 2005;73:3044–3052.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhao T, Cheng X, et al. Cortical inflammation is increased in a DSS-induced colitis mouse model. Neurosci Bull. 2018;34:1058–1066.
   PubMed Web of Science ®Google Scholar
• Pan LF, Yu L, Wang LM, et al. The toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats. Mol Med Rep. 2017;16:3863–3868.
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Tsuchimori N, Matsumoto T, et al. TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79:34–41.
   PubMed Web of Science ®Google Scholar
• Gaikwad S, Agrawal-Rajput R. Lipopolysaccharide from Rhodobacter sphaeroides attenuates microglia-mediated inflammation and phagocytosis and directs regulatory T cell response. Int J Inflam. 2015;2015:1–13.
   Google Scholar
• Thorgersen EB, Macagno A, Rossetti C, et al. Cyanobacterial LPS antagonist (CyP)-A novel and efficient inhibitor of Escherichia coli LPS-induced cytokine response in the pig. Mol Immunol. 2008;45:3553–3557.
   PubMedGoogle Scholar
• Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–934.
   PubMed Web of Science ®Google Scholar
• De Paola M, Mariani A, Bigini P, et al. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971–981.
   PubMed Web of Science ®Google Scholar
• Lei C, Wu B, Cao T, et al. Brain recovery mediated by toll-like receptor 4 in rats after intracerebral hemorrhage. Brain Res. 2016;1632:1–8.
   PubMed Web of Science ®Google Scholar
• Pålsson-McDermott EM, O’Neill LAJ. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology. 2004;113:153–162.
   PubMed Web of Science ®Google Scholar
• Morefield GL, Hawkins LD, Ishizaka ST, et al. Synthetic toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin Vaccine Immunol. 2007;14:1499–1504.
   PubMedGoogle Scholar
• Wang X, Quinn PJ. Lipopolysaccharide: biosynthetic pathway and structure modification. Prog Lipid Res. 2010;49:97–107.
   PubMed Web of Science ®Google Scholar
• Michaud J-P, Halle M, Lampron A, et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology. Proc Natl Acad Sci. 2013;110:1941–1946.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–151.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488–496.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Crain B, Yao S, et al. Novel synthetic toll-like receptor 4/MD2 ligands attenuate sterile inflammation. J Pharmacol Exp Ther. 2014;350:330–340.
   PubMed Web of Science ®Google Scholar
• Neve JE, Wijesekera HP, Duffy S, et al. Euodenine A: a small-molecule agonist of human TLR4. J Med Chem. 2014;57:1252–1275.
   PubMed Web of Science ®Google Scholar
• Niu X, Yu Y, Guo H, et al. Molecular modeling reveals the inhibition mechanism and binding mode of ursolic acid to TLR4-MD2. Comput Theor Chem. 2018;1123:73–78.
   Web of Science ®Google Scholar
• Goff PH, Hayashi T, Martínez-Gil L, et al. Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol. 2015;89:3221–3235.
   PubMed Web of Science ®Google Scholar
• Hawkins LD. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther. 2003;300:655–661.
   Web of Science ®Google Scholar
• Przetak M, Chow J, Cheng H, et al. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine. 2003;21:961–970.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Nakamura S, Seki M, et al. Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae. Clin Vaccine Immunol. 2013;20:977–985.
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316:1628–1632.
   PubMed Web of Science ®Google Scholar
• Ishizaka ST, Hawkins LD. E6020: a synthetic toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines. 2007;6:773–784.
   PubMed Web of Science ®Google Scholar
• Rego Â, Viana SD, Ribeiro CAF, et al. Monophosphoryl lipid A: a promising tool for Alzheimer’s disease toll. J Alzheimer’s Dis. 2016;52:1189–1202.
   PubMedGoogle Scholar
• Nakamura S, Iwanaga N, Seki M, et al. Toll-like receptor 4 agonistic antibody promotes host defense against chronic pseudomonas aeruginosa lung infection in mice. Infect Immun. 2016;84:1986–1993.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Fukudome K, Takao S, et al. Reduced surface expression of TLR4 by a V254I point mutation accounts for the low lipopolysaccharide responder phenotype of BALB/c B cells. J Immunol. 2013;190:195–204.
   PubMed Web of Science ®Google Scholar
• Russell R, Brightling CE. Anti-IL-5 for severe asthma: aiming high to achieve success. Chest. 2016;150:766–768.
   PubMed Web of Science ®Google Scholar
• Rosenzweig HL, Lessov NS, Henshall DC, et al. Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke. 2004;35:2576–2581.
   PubMed Web of Science ®Google Scholar
• Broad A, Jones D, Kirby J. Toll-like receptor (TLR) response tolerance: a key physiological “damage limitation” effect and an important potential opportunity for therapy. Curr Med Chem. 2006;13:2487–2502.
   PubMed Web of Science ®Google Scholar
• Liu H, Xin L, Chan BPL, et al. Interferon-β administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neurosci Lett. 2002;327:146–148.
   PubMed Web of Science ®Google Scholar
• Marsh B, Stevens SL, Packard AEB, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci. 2009;29:9839–9849.
   PubMed Web of Science ®Google Scholar
• Pourbadie HG, Sayyah M, Khoshkholgh-Sima B, et al. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer’s disease–related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiol Aging. 2018;70:203–216.
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Gholami Pourbadie H, Sayyah M, et al. Neuroprotective effect of monophosphoryl lipid A, a detoxified lipid A derivative, in photothrombotic model of unilateral selective hippocampal ischemia in rat. Behav Brain Res. 2018;347:26–36.
   PubMed Web of Science ®Google Scholar
• Deleu D. Rivastigmine in the treatment of Alzheimer’s disease. Eur Neurol. 2001;46:110.
   PubMed Web of Science ®Google Scholar
• Okun E, Griffioen KJ, Gen Son T, et al. TLR2 activation inhibits embryonic neural progenitor cell proliferation. J Neurochem. 2010;114:462–474.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hattori K, Hamanaka J, et al. Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia. Sci Rep. 2012;2:896.
   PubMed Web of Science ®Google Scholar